KumbyAI is the AI-powered analyst that synthesizes news, identifies risks, and delivers actionable intelligence for quality and compliance professionals. Stop chasing headlines and start anticipating what's next.
A real-time look at the news KumbyAI is analyzing right now.
Endpoints News · 16 minutes ago
The new negotiated prices for Novo Nordisk’s GLP-1 drugs under the Inflation Reduction Act have raised questions about how they will impact the prices Novo agreed to under its separate “most favored nation” deal with ...
Endpoints News · about 1 hour ago
Alkermes wins. On Wednesday, Danish drugmaker Lundbeck said it was giving up on its effort to try to steal Avadel from a $2.1 billion deal with Alkermes signed ...
Endpoints News · about 2 hours ago
Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...
Pharmaceutical Technology · about 2 hours ago
The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad
Pharmaceutical Technology · about 2 hours ago
The second round of IRA negotiations brings the total number of negotiated drugs to 25.
Pharmaceutical Technology · about 2 hours ago
Novartis' Stein site will discontinue solid dose manufacturing in favour of sterile dose and cell & gene therapy production, which will see 550 job cuts by EOY 2027.